Updated 10:08 GMT, 20 Nov 2026 SPX 7,175.83 -2.02% NDX 26,517.05 -2.21% VIX 29.83 +4.89% GOLD 3,571.10 -3.10% CL 80.86 -2.82% BTC 61,746.00 -0.25%
NAS100 26,517 −2.21% S&P 7,176 −2.02% GOLD $3,571 −3.10% BTC $61,746 −0.25% VIX 29.83 +4.89% latest tape · as of 10:08 UTC
The Screen · Technology · Semiconductors

Texas Instruments logoTexas Instruments

TXN · a US exchange · USD · Market cap $270.4B · 33,000 employees

Texas Instruments Incorporated designs, manufactures, and sells semiconductors to electronics designers and manufacturers in the United States, China, the rest of Asia, Europe, the Middle East, Africa, Japan, and internationally.

FAIL · Does not pass the screen
285.75 USD

Price as of 19 Nov 2026Daily close, not a live quote

Screened 2026-11-19 · the tape above runs as of 10:08 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price285.75 USD at the 19 Nov 2026 close
  • Our value readOvervalued vs our fair value, as of 19 Nov 2026
  • Our regime readMarkup, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • OptionsOpen interest leans slightly to calls (put/call 0.72)
  • Last reviewed19 Nov 2026 (1 day ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: $218.86 to $251.69, base estimate $218.86 (screen dated 2026-11-19).

Current read
Markup ?
Overvalued · screened 2026-11-19
  • Trend Markup
  • Insiders insiders sold, $1,882,515, latest filing 2026-10-29
  • Positioning political selling, disclosed 2026-10-14
  • Options put/call open interest 0.72, read 2026-11-18
  • Ethical does not pass the values gate
Price285.75 USD
Fair value218.86
Ethical score10.0/100
Value readOvervaluedas of 19 Nov 2026
Our investment reviews on this name
2026-11-18Read Markup295.86-3.4% to today Distribution gives way to Markup first Markup read since November
2026-11-11Read Distribution300.52-4.9% to today ✓Markup gives way to Distribution first Distribution read since August
2026-11-04Read Markup312.49-8.6% to today Accumulation gives way to Markup after a 12% rise in 5 weeks
2026-10-02Read Accumulation278.07+2.8% to today ✓Distribution gives way to Accumulation with volume flow in agreement

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its markup label.

Texas Instruments holds its Markup at $285.75. Elevated stress, defensive posture warranted, held for 11 days.

As held on the ledger · 2026-11-19
PhaseMarkup
Quantitative stateElevated stress, defensive posture warranted, held for 11 days
Price at the screen$285.75
Valuation38.36 trailing · 25.57 forward price to earnings
Values screenFAIL · score 10.0
Beta1.39
The Workings

Five Screens: TXN's Results

FAIL. Debt ratio

TestFigureLimitStatus
Business activity Permissible Permissible core business Pass
Debt load 40.62% Below 33% Fail
Interest-bearing cash 4.79% Below 33% Pass
Receivables 15.00% Below 49% Pass

Definitions, sources and threshold rules: ticker values-screen methodology.

The Ethical Read

Why It Falls Short, in Plain English

Texas Instruments's business is in a permissible area, but its interest-bearing debt is about 41% of the company, well over the ~33% line, so it does not pass on the financial screens.

Read as at 2026-11-19. It updates when the underlying figures move, and past reads are kept below.

Follow this verdict

Get an email when TXN's ethical verdict changes

Today TXN does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Our analysis reads Overvalued vs our fair value, as of 19 Nov 2026: it trades above our $218.86 fair value estimate, strong competitive moat, 27.70% revenue growth.

Model construction and limits: fair-value methodology.

218.86Conservative218.86Base case251.69Growth case 285.75Price

Fair value range in USD, drawn from the 2026-11-19 screen. The gold marker is the market price at the same screen. The price runs 30.6% above the base estimate.

The Street's Range
250.00Street low 340.00Street average 400.00Street high 285.75Price

Third-party analyst targets: 29 covering, consensus Buy. The average target sits +19% from the screen price.

Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.

Price History & Projections

Where our models see it going: fair-value estimate $218.86, with a range of $218.86 to $251.69, dated to the 2026-11-19 screen.

How our estimate and third-party targets differ.

The Business, in Plain Words

Texas Instruments: Failing the Ethical Gauge in a Cyclical Storm

Imagine electronics designers worldwide racing to create the next gadget, and Texas Instruments is their go-to for semiconductors. The company operates in a highly cyclical industry, experiencing robust revenue growth of 23%, with a profit margin of 31% and a robust return on equity rating of 35%, highlighting its strong competitive moat. However, the market's optimism has the stock priced at a substantial 19% premium over our fair value estimate, which is a red flag in a cyclical industry.

The cyclical nature of the semiconductor industry poses a special risk. Currently, the company's valuation is high, which is typically a warning sign rather than a bargain, especially during peak earnings periods in such industries. A low multiple following a period of high earnings could indicate a cyclical value trap.

Unfortunately, despite its strong financial performance, Texas Instruments fails our ethical screen due to a concerning debt ratio. This is a critical factor in our evaluation process, as sustainable practices are as important as financial success. The consensus rating from analysts is a 'buy' with a median target price of $340, yet it's essential to consider not just the potential returns but the ethical standards of an investment.

Analysis, not advice.

The fundamentals · plain-English read
Forward P/E25.6xfairly priced for its growth rate
Trailing P/E38.4xexpensive: the price assumes strong growth ahead
EPS, trailing7.71
EPS, forward11.56
Revenue growth+27.7%strong top-line growth
Profit margin34.3%highly profitable on every dollar of sales
Return on equity39.7%an exceptional return on shareholder capital
FCF yield1.77%
Dividend yield1.84%
Debt to equity0.71moderate, manageable leverage
Current ratio5.60comfortably covers its short-term bills
Beta1.39moves a little more than the market
Short interest, float0.02%
52-week range152.73 - 334.03
MoatSTRONG
Market cap$270.4B
Employees33,000

TXN-specific watchpoints · The things to watch: it already moves more than the market on an average day.

Metric definitions and interpretation rules: ticker-page methodology.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-18 Markup · changed $295.86 -1.6% Entry 23

The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 1.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 43%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (32 analysts) rates it buy, with a mean price target of $285.

2026-11-11 Distribution · changed $300.52 -3.8% Entry 22

The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 3.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 43%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (32 analysts) rates it buy, with a mean price target of $285.

2026-11-04 Markup · changed $312.49 +12.0% Entry 21

The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 12.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 21% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 43%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (32 analysts) rates it buy, with a mean price target of $285.

2026-10-28 Accumulation $279.12 +0.0% Entry 20

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 21% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 43%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (32 analysts) rates it buy, with a mean price target of $285.

2026-10-21 Accumulation $279.12 +0.0% Entry 19

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 21% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 43%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (32 analysts) rates it buy, with a mean price target of $285. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-20 Accumulation $279.12 +0.0% Entry 18

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 21% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 43%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (32 analysts) rates it buy, with a mean price target of $285. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-19 Accumulation $279.12 +0.0% Entry 17

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 21% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 43%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (32 analysts) rates it buy, with a mean price target of $285. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-18 Accumulation $279.12 +0.0% Entry 16

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 63% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 43%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (32 analysts) rates it buy, with a mean price target of $285. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-17 Accumulation $279.12 +0.0% Entry 15

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 63% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 43%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (32 analysts) rates it buy, with a mean price target of $285. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-16 Accumulation $279.12 -1.6% Entry 14

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 1.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 63% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 43%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (32 analysts) rates it buy, with a mean price target of $285. It reported earnings in this window, a natural checkpoint for the thesis.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

Latest News · What the Market Is Reading on TXN

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in TXN's Space

Screened names in the same industry · explore each on its own page.

The Insider Ledger · Form 4 Filings, As Filed
Most recent filings · TXN
DateInsiderTitleTypeSharesValue
2026-10-29 Kirk Ronald Dir S - Sale+OE 6,065 $1,882,515
2026-10-27 Clark Janet F Dir S - Sale+OE 4,306 $1,302,404
2026-10-27 Patsley Pamela H Dir S - Sale+OE 4,532 $1,366,670
2026-10-27 Sanchez Robert E Dir S - Sale+OE 6,065 $1,832,923
2026-05-14 BAHAI AHMAD Officer 5,000 $1,545,636
2026-05-14 LIZARDI RAFAEL R Chief Financial Officer 47,734 $14,706,996
2026-05-14 BAHAI AHMAD Officer 5,000 $550,750
2026-05-14 LIZARDI RAFAEL R Chief Financial Officer 47,734 $8,344,381
2026-05-13 COX CARRIE SMITH Director 8,838 $2,708,029
2026-05-13 COX CARRIE SMITH Director 8,838 $947,492

Public filings, recorded as found. The full tape lives at Insider Intelligence.

The Political Ledger · Congressional Disclosures
Disclosures naming TXN
DatePoliticianPartyTypeAmount
2026-10-14 Kevin Hern Republican sell 15K–50K
2026-10-14 Kevin Hern Republican sell 15K–50K
2026-10-14 Kevin Hern Republican sell 15K–50K
2026-10-13 Ro Khanna Democrat buy 1K–15K
2026-10-07 Ro Khanna Democrat buy 15K–50K
What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $297.76 -5.3% · $947 -5.3%
2 months $213.64 +32.0% $1.42 $1,327 +32.7%
3 months $189.09 +49.1% $1.42 $1,499 +49.9%
6 months $179.58 +57.0% $2.84 $1,586 +58.6%
1 year $196.77 +43.3% $5.62 $1,462 +46.2%
2 years $186.75 +51.0% $11.00 $1,569 +56.9%
3 years $156.26 +80.5% $16.14 $1,908 +90.8%
5 years $163.68 +72.3% $25.48 $1,879 +87.9%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever TXN does next, these words stay.

Texas Instruments · TXN · Markup · $285.75
Recorded 2026-11-19 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.